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When should patients
with mitral valve prolapse 
get endocarditis prophylaxis?
■ EVIDENCE-BASED ANSWER
Patients with suspected mitral valve prolapse
(MVP) (Figure 1) should undergo echocardiog-
raphy before any procedure that may place
them at risk for bacteremia. Patients with MVP
and documented absence of mitral regurgitation
or valvular thickening likely do not need anti-
biotic prophylaxis against subacute bacterial
endocarditis (SBE). Patients with MVP with
documented mitral regurgitation, valvular
thickening, or an unknown degree of valvular
dysfunction may benefit from antibiotics during
procedures that often lead to bacteremia
(strength of recommendation: C).1
■ EVIDENCE SUMMARY
Only disease-oriented evidence and expert opin-
ion address prevention for endocarditis. A 
randomized trial would require an estimated
6000 patients to demonstrate benefit.2
Endocarditis occurs in MVP at a rate of 0.1
cases/100 patient-years.3 However, MVP is the
most common predisposing/precipitating cause
of native valve endocarditis.4,5 In animal mod-
els, antibiotics prevent endocarditis following
experimental bacteremia. The antibiotic can be
administered either just before or up to 2 hours
after the bacteremic event.2 It is worth noting
that most bacteremia is not associated with
medical procedures. Since endocarditis is often
fatal, recommendations have been developed
based on these animal models. Estimates of
effectiveness of prophylaxis from case-control
studies in humans (not limited to patients with
MVP) estimate effectiveness from 49% to 91%.2
For patients with MVP who do not have 
evidence of mitral regurgitation on physical
examination or echocardiography, the risk of
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Mitral valve prolapse 
involves the degeneration of the mitral valve,
dilation of the mitral annulus, abnormal chordal
insertions, redundant mitral leaflet tissue that
bulges into the left atrium during systole, and
elongated chordae. Stethoscopic exam will
reveal a mid-systolic click followed by a regur-
gitation murmur. A completely degenerated
valve leads to mitral regurgitation.
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Recommended prophylactic regimens for mitral valve prolaspe
Situation Medication Dosage
Dental, oral, respiratory,
esophageal procedures 1 hour before procedure
Standard prophylaxis Amoxicillin Adult: 2 g Child: 50 mg/kg
Allergy to penicillin Clindamycin Adult: 600 mg Child: 20 mg/kg
Cephalexin Adult: 2 g Child: 50 mg/kg
Azithromycin Adult: 500 mg Child: 15 mg/kg
Genitourinary or non-esophageal 
gastrointestinal procedures
Moderate-risk patients Amoxicillin Adult: 2 g Child: 50 mg/kg
1 hour before procedure
Moderate-risk patients Vancomycin Adult: 1 g IV Child: 20 mg/kg IV
allergic to penicillin Administer over 1-2 hrs; complete 30 minutes before procedure
High-risk patients Add gentamicin 1.5 mg/kg (up to 120 mg) IV to be completed 30 minutes 
to amoxicillin before procedure. If not allergic to penicillin, give penicillin
or vancomycin give penicillin, give amoxicillin 1 g 6 hours after
Modified from Dajani 1997.1
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morbidity may be greater from antibiotic thera-
py than the risk of endocarditis. Prophylaxis for
these patients is not recommended. Patients
with MVP associated with regurgitation are at
moderate risk and may benefit from antibiotic
prophylaxis. 
■ RECOMMENDATIONS FROM OTHERS
The American Heart Association has published
recommendations in 1985,6 1990,7 and 1997.1
The 1997 recommendations are summarized 
in Figure 2. The Swiss Working Group for
Endocarditis Prophylaxis published similar rec-
ommendations in 2000.8 Recommended prophy-
lactic regimens appear in Table 1. Table 2
shows a modified list of procedures for which
prophylaxis is recommended.
Daniel Triezenberg, MD, Jennifer Helmen, BA,
Michelle Pearson, MD, Saint Joseph Regional Medical
Center, South Bend, Ind
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Procedures for which 
endocarditis prophylaxis is,
or is not, recommended
Endocarditis prophylaxis recommended 
Respiratory tract
Tonsillectomy or adenoidectomy
Surgical operations that involve respiratory mucosa
Bronchoscopy with a rigid bronchoscope
Gastrointestinal tract
Sclerotherapy for esophageal varices
Esophageal stricture dilation
Endoscopic retrograde cholangiography with 
biliary obstruction
Biliary tract surgery
Surgical operations that involve intestinal mucosa
Genitourinary tract
Prostatic surgery
Cystoscopy
Urethral dilation
Endocarditis prophylaxis not recommended 
Respiratory tract
Endotracheal intubation
Flexible bronchoscopy, with or without biopsy
Tympanostomy tube insertion
Gastrointestinal tract
Endoscopy with or without gastrointestinal biopsy
Genitourinary tract
Circumcision
Vaginal hysterectomy
Vaginal delivery
Cesarean section
In uninfected tissue
Incision or biopsy of surgically scrubbed skin
Urethral catheterization
Uterine dilatation and curettage
Therapeutic abortion
Sterilization procedures
Insertion or removal of intrauterine devices
Cardiac
Transesophageal echocardiography
Cardiac catheterization, including balloon 
angioplasty and coronary stents
Implanted cardiac pacemakers, 
implanted defibrillators
Modified from Dajani et al, 1997.1
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■ CLINICAL COMMENTARY
Guidelines assist decision-making
regarding who needs SBE prophylaxis
It is unfortunate, but not surprising, that the
evidence for SBE prophylaxis for patients with
MVP is disease-oriented evidence and expert
opinion. Too often, the easy thing to do in a busy
practice is not necessarily in the best interest of
either the patient or the public. However—
despite the low incidence of SBE—the high
mortality of the disease and community stan-
dard of care often drive clinicians to write that
prescription for antibiotics. 
With the improved resolution and sensitivity
of newer generations of echocardiograms, clini-
cians often face the dilemma of the patient with
MVP and “trivial” or “minimal” mitral regurgi-
tation. Unfortunately, no guidelines assist us in
our decision-making regarding these patients.
Another consideration for the clinician is the
American Heart Association’s recommendation
for SBE prophylaxis for patients with MVP and
thickened leaflets, regardless of whether there
is associated mitral valve regurgitation. 
One significant change that should lessen the
frequency of unnecessary antibiotic prescribing
was published recently. The echocardiographic
criteria for diagnosing MVP were changed in
the 2003 updated guidelines from the American
College of Cardiology, American Heart
Association, and American Society of
Echocardiography. Valve prolapse of 2 mm or
more above the mitral annulus is required for
diagnosis.10 This change has effectively lowered
the prevalence of MVP from 4% to 8% of the
general population down to 2% to 3%. 
David M. Bercaw, MD, Christiana Care Health Systems,
Wilmington, Del
Determining the need for antibiotic prophylaxis
for patients with mitral valve prolapse
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YES
Prophylaxis
YES
NO
▲
▲
▲
▲
▲
Patient with suspected mitral valve prolapse must undergo 
invasive procedure
Is there confirmed murmur of mitral regurgitation?
Presence of mitral regurgitation not determined. Is the need for
the procedure urgent?
NO
NO
▲
Lack of significant mitral regurgitation makes prophylaxis 
unnecessary
YESRefer for evaluation. Is there evidence of murmur or echocardio-
graphic/Doppler demonstration of mitral regurgitation?
